Evidence map›Paper›PMID 22734853›Full record

ArticleOmics : a journal of integrative biology

Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis.

Prabhakar Chalise, Anthony Batzler, Ryan Abo, Liewei Wang, Brooke L Fridley

Abstract read
In one paragraph

Article in Omics : a journal of integrative biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Nanotheranostics for personalized medicine.Expert review of molecular diagnostics · 2013
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prabhakar ChaliseBiostatistics Department, University of Kansas Medical Center, Kansas City, Kansas, USA.
Anthony Batzler
Ryan Abo
Liewei Wang
Brooke L Fridley

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI COHEN, PETER A · 2004 to 2018
$32.7M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI, WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
Pharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5M
Role of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI CHARI, SURESH T. · 2003 to 2003
$1.5M
Pharmacogenomics of a Cytidine Analogue, GemcitabineK22CA130828 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2008 to 2010
$492k
Integrative genomic models for analysis of pharmacogenomic studiesR21CA140879 · NCI · MAYO CLINIC ROCHESTER · PI FRIDLEY, BROOKE L · 2009 to 2010
$299k
Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studiesR21GM086689 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2011 to 2012
$232k
NCI NIH HHS CA102701NCI NIH HHS CA130828NCI NIH HHS CA138461NCI NIH HHS CA140879NCI NIH HHS P50 CA102701NIGMS NIH HHS GM61388NIGMS NIH HHS GM86689
6 · The paper itself

Abstract

Variation in drug response results from a combination of factors that include differences in gender, ethnicity, and environment, as well as genetic variation that may result in differences in mRNA and protein expression. This article presents two integrative analytic approaches that make use of both genome-wide SNP and mRNA expression data available on the same set of subjects: a step-wise integrative approach and a comprehensive analysis using sparse canonical correlation analysis (SCCA). In addition to applying standard SCCA, we present a novel modification of SCCA which allows different weighting for the various pair-wise relationships in the SCCA. These integrative approaches are illustrated with both simulated data and data from a pharmacogenomic study of the drug gemcitabine. Results from these analyses found little overlap in terms of genes detected, possibly detecting different biological mechanisms. In addition, we found the proposed weighted SCCA to outperform its unweighted counterpart in detecting associations between the genomic features and phenotype. Further research is needed to develop and assess new integrative methods for pharmacogenomic studies, as these types of analyses may uncover novel insights into the relationship between genomic variation and drug response.

Indexed as

AlgorithmsData Interpretation, StatisticalAntimetabolites, AntineoplasticCell LineComputer SimulationDeoxycytidineGemcitabineGene ExpressionGene Regulatory NetworksGenesGenetic Association StudiesGenotypeHumansInhibitory Concentration 50Models, GeneticPolymorphism, Single NucleotideAntimetabolites, AntineoplasticDeoxycytidineGemcitabine

Identifiers

PMID22734853
PMCPMC3394856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.